Compare Incyte Corporation (INCY) vs Samsara Inc (IOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Samsara Inc — how do they compare? Incyte Corporation trades at $120.59 (market cap $24.54B), while Samsara Inc trades at $38.84 (market cap $23.49B). The key difference: Incyte Corporation and Samsara Inc are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Samsara Inc nearer its low. Which is the better fit depends on your goals.
| INCY | IOT | |
|---|---|---|
Market Cap | $24.54B | $23.49B |
Sector | Health | Technology |
52-Week High | $129.93 | $45.22 |
52-Week Low | $81.61 | $24.25 |
Enterprise Value | $20.04B | $22.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Samsara (IOT) trades at $38.77, down 2.73% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. Recent earnings beats and strong analyst consensus (77.8% buy ratings) support optimism, while the company projects revenue growth to $1.7B in 2026 with a return to profitability. The stock's high P/E of 403.2 reflects growth expectations amid expanding AI adoption in its connected operations platform.
Outlook remains positive with a consensus price target of $44.50, offering 14.8% upside, driven by execution on large customer growth and margin expansion. Key risks include high valuation sensitivity to earnings misses, competitive pressures in software, and macroeconomic impacts on operational spending. Institutional accumulation, such as Arrowstreet Capital's 77.1% stake increase in Q1 2026, underscores confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
